Detail akcie Moberg Pharma Rg online

Business Summary: Moberg Pharma AB (publ), formerly Moberg Derma AB (publ) is a Sweden-based pharmaceutical company. The Company is a pharmaceutical company in dermatology focused on the commercialization of proprietary drugs based on proven substances. Moberg Pharma AB (publ) develops MOB-015, the treatment of nail fungus. Its product portfolio includes products for the treatment of skin diseases, pain, the treatment of nails damaged by fungus or psoriasis, dry and damaged feet and range of products for several types of skin and scalp problems. The Company deals with development, manufacture, direct and indirect sale, marketing and licensing of pharmaceuticals, medical devices and skin care products as well as related activities.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Moberg Pharma AB (publ) revenues increased 31% to SEK11.5M. Net loss increased 23% to SEK14.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Medical Products segment loss increase of 19% to SEK19.9M. Basic Earnings per Share excluding Extraordinary Items increased from -SEK0.39 to -SEK0.31.